@article{76c3682f57b54be5915acf8922d81b39,
title = "Retinal imaging in Alzheimer's and neurodegenerative diseases",
abstract = "In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. The Alzheimer's Association and the Alzheimer's & Dementia: Diagnosis, Assessment, Disease Monitoring editorial team (companion journal to Alzheimer's & Dementia) convened an interdisciplinary discussion in 2019 to identify a path to expedite the development of retinal biomarkers capable of identifying biological changes associated with AD, and for tracking progression of disease severity over time. As different retinal imaging modalities provide different types of structural and/or functional information, the discussion reflected on these modalities and their respective strengths and weaknesses. Discussion further focused on the importance of defining the context of use to help guide the development of retinal biomarkers. Moving from research to context of use, and ultimately to clinical evaluation, this article outlines ongoing retinal imaging research today in Alzheimer's and other brain diseases, including a discussion of future directions for this area of study.",
keywords = "Alzheimer's disease, biomarkers, early detection, eye, neurodegeneration, retina, retinal imaging",
author = "Snyder, {Peter J.} and Jessica Alber and Clemens Alt and Bain, {Lisa J.} and Bouma, {Brett E.} and Bouwman, {Femke H.} and DeBuc, {Delia Cabrera} and Campbell, {Melanie C.W.} and Carrillo, {Maria C.} and Chew, {Emily Y.} and Cordeiro, {M. Francesca} and Due{\~n}as, {Michael R.} and Fern{\'a}ndez, {Brian M.} and Maya Koronyo-Hamaoui and {La Morgia}, Chiara and Carare, {Roxana O{\textquoteright}} and Sadda, {Srinivas R.} and {van Wijngaarden}, Peter and Snyder, {Heather M.}",
note = "Funding Information: The workshop was fully funded by the Alzheimer's Association. Authors are supported in part by the following: P.J. Snyder: the Morton Plant Mease Health Care Foundation, Clearwater, FL., USA.; Brett E. Bouma: NIH (grant P41EB-015903). Delia Cabrera DeBuc: the Finker Frenkel Legacy Foundation and the Alzheimer's Association (AARGD-17-531255). M. Koronyo-Hamaoui: the NIH/NIA R01 AG055865 and R01 AG056478 awards. P. vW: Yulgilbar Alzheimer's Research Program, Pratt Foundation, Joan Margaret Ponting Charitable Trust & Hecht Charitable Trust (Perpetual), National Foundation for Medical Research and Innovation, Alzheimer's Drug Discovery Foundation. M. Campbell: the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Institutes of Health Research, Canada (CIHR). The authors wish to acknowledge the team who provided significant logistical, coordination and administrative support in the planning of the RIA D workshop and the preparation of the report on its proceeding: Ms. A shley Hansen; Ms. Meredith McNeil, Ms. Patricia Correia and Dr. A pril Q. Ross. Funding Information: B. Bouma has patents related to OCT instrumentation and signal processing, which are assigned to Mass General Hospital and licensed to Heidelberg Engineering. M.C. Carrillo and H.M. Snyder are full time employees of the Alzheimer's Association. M. Campbell is a member of the board of directors of LumeNeuro, a shareholder in LumeNeuro, and holds related patents through the University of Waterloo. M. Due{\~n}as was a full time employee of the American Optometric Association when this conference took place. B. Fern{\'a}ndez is a full time employee of Heidelberg Engineering. M. Koronyo‐Hamaoui is a co‐founder, minor shareholder, and consultant of NeuroVision Imaging, Inc. C. La Morgia received speaker honoraria and meeting reimbursement from Santhera Pharmaceuticals and receives funding from the Italian Ministry of Health (GR‐2013‐02358026). S.R. Sadda received honoraria from Topcon, Nidek, Heidelberg, Centervue, Optos, Amgen, Allergan, Novartis, Roche/ Genentech, Oxurion, 4DMT, and Merck; and he also received research instruments from Topcon, Nidek, Carl Zeiss Meditec, Centervue, Heidelberg, and Optos. P. van Wijngaarden is a founder of Enlighten Imaging PTY LTD, a start‐up company focused on developing novel retinal imaging solutions for neurological and retinal diseases. Funding Information: The workshop was fully funded by the Alzheimer's Association. Authors are supported in part by the following: P.J. Snyder: the Morton Plant Mease Health Care Foundation, Clearwater, FL., USA.; Brett E. Bouma: NIH (grant P41EB‐015903). Delia Cabrera DeBuc: the Finker Frenkel Legacy Foundation and the Alzheimer's Association (AARGD‐17‐531255). M. Koronyo‐Hamaoui: the NIH/NIA R01 AG055865 and R01 AG056478 awards. P. vW: Yulgilbar Alzheimer's Research Program, Pratt Foundation, Joan Margaret Ponting Charitable Trust & Hecht Charitable Trust (Perpetual), National Foundation for Medical Research and Innovation, Alzheimer's Drug Discovery Foundation. M. Campbell: the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Institutes of Health Research, Canada (CIHR). Publisher Copyright: {\textcopyright} 2020 Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",
year = "2021",
month = jan,
doi = "10.1002/alz.12179",
language = "English (US)",
volume = "17",
pages = "103--111",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "1",
}